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This paper will concentrate on Chlamydia pneumoniae, 
whch is the most common non-viral intracellular 
pathogen and has been a major focus of this 
Symposium. It has now been 10 years since we first 
obtained serologic evidence suggesting that the 
untypeable Chlamydia isolate obtained from the eye of 
a child in Taiwan in 1965 was associated with 
respiratory tract infection [l], and then isolated a s d a r  
strain from acute respiratory hsease 121. While much 
circumstantial evidence has accumulated that the 
TwAR organism causes acute respiratory disease, there 
have been very few appropriately controlled investi- 
gations directed at proving an etiologic role for the 
organism in acute respiratory disease (ARD) [3]. 
EPIDEMIOLOGY OF C. PNEUMONAEINFECTION 
A characteristic of TWAR infections has been period- 
icity [4]. Some years may have a h g h  incidence and 
others a much lower incidence. Epidemics occur which 
are overlaid on endemic infection with variable 
incidence. Overall, C. pneumoniae infection can be 
identhed in about 10% of all pneumonias, suggesting 
it is the third or fourth most common etiologic agent 
(Table 1). It also accounts for about 5% of bronchitis 
and sinusitis, as estimated from current information. 
Estimating the frequency of TWAR infection in 
pharyngitis is more difficult (see below). 
Table 1 Respiratorv diseaies caused by W A R  
~~ 
Aeuologc asociauon estabhhed 
Pneumorua 
Bronchus 
10% 
5% 
Aetiologc association well supported 
Sinusitis 5% 
Pharyngitis 2% 
T W m  causality proposed 
Otitis media 
Asthma 
A general outline of the epidemiology of C. 
pneumoniae infection has been obtained by sero- 
epidemiology, and it seems unlikely that future studies 
will alter these general concepts [5,6]. Infection with 
the TWAR organism is widespread and frequent. In 
most populations virtually everyone is infected and 
reinfected during their ldetime [7]. In temperate zone 
developed countries, the lughest rate of new infections 
(incidence) is between the ages of 5 and 15 [8,9]. In 
adults most infections are reinfections and they 
continue to occur into old age [lo]. 
Table 2 presents a list of questions for future 
investigation concerning acute respiratory infection. 
Most infections with C. pneumoniae are asymptomatic, 
and it is unknown what factors are involved in causing 
a symptomatic disease following TWAR infection. Age 
appears to be an important host factor, in that clddren 
have fewer symptomatic infections than adults, but 
there must be other host, organism and environmental 
factors. 
Transmission is from person to person via the 
respiratory tract without intermehate hosts. It is 
unknown whether true airborne infection occurs as it 
does with C. psittaci [l l] .  Transmission appears to be 
inefficient, with single infections occurring most 
frequently in households [8], although documented 
Table 2 C.  pneumoniae (TWAR) infection: questions for 
future investigation 
Factors for symptomatic infection 
Airborne transmission 
Etiology in U R I  
Why male > female? 
Carriers 
Dual infection 
Immunity, immunopathology 
Simple rapid diagnostic test 
Idenhfy spec& antigen 
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household outbreaks suggest that some infected persons 
are more efficient at spreading the organism [12-151. 
The incubation period averages 21 days [13]. Epi- 
demics occurring in closed populations are prolonged 
(4-7 months) due both to the longer incubation period 
and the inefficiency of transmission [ 16,171. 
Among the unexplained facts about WAR 
infection is the higher seroprevalence of antibody and 
increased incidence of recognized infections in adult 
males versus females. The antibody prevalence in males 
after age 20 has been higher than in females in virtually 
all studies fivm around the world [7,18-221. In several 
studies of general populations, includmg family studies, 
males had a higher rate of new infection [8]. 
C. PNEUMONlAE IN UPPER RESPIRATORY 
TRACT INFECTION 
While there has been evidence presented for an 
etiologic role of C. pneumoniae in pneumonia and 
bronchitis 231, it is less certain what role the organism 
plays in upper respiratory infections. Pharyngitis and 
sinusitis fiequently accompany TWAR pneumonia and 
bronchitis. Also, pharyngitis may precede (biphasic 
onset) and sinusitis may follow (complication) lower 
respiratory tract TWAR infections. Both sinusitis and 
pharyngitis without lower respiratory tract disease have 
been associated with mm infection. But there have 
not been the type of controlled etiologic studies that 
would make certain that h s  association is causal. In the 
hture, advantage should be taken of epidemics, 
utilizing modern diagnostic methods with both iso- 
lation and polymerase chain reaction (PCR) for 
demonstration of the organism and microimmuno- 
fluorescence (MIF) serology with appropriately timed 
sera, to better understand the causal role of C. 
pneumoniae in upper respiratory infections. 
IMMUNITY AND CARRIAGE 
There is only limited information on the role of 
immunity in TWAR respiratory tract mfection. Persons 
with the reinfection antibody pattern have been shown 
to have milder disease than those with a primary 
infection antibody pattern. This has been true in studies 
of both young and middle-aged adults [17,23]. 
Immunity following C. pneumoniae infection is 
obviously not absolute or long-lasting since reinfection 
of adults is so common. This partial temporary 
immunity is similar to that seen with C. psittaci in 
workers repeatedly exposed in duck and turkey 
processing plants. It is not known if the immuno- 
pathology which is associated with C. truchomutis 
infection occurs with C .  pneumoniae [24]. 
Another area of C. pneumoniae respiratory infection 
that awaits hture clarification concerns carriage of the 
organism in the respiratory tract without active 
infection. That asymptomatic infections with W A R  
are common was demonstrated in the early studies of 
Finnish military epidemics, where only one in 10 
infections resulted in recognized disease [16]. More 
recently, Hammerschlag and others have isolated the 
organism fiom the throats of asymptomatic individuals 
both with and without a history of prior illness 
[25-281. These findings are useful in two ways: to 
determine the role that such ‘carriers’ might play in 
transmission, and to determine if this Occurrence is 
common enough to indda te  demonstration of the 
organism in the pharynx as the sole means of diagnosis 
of the etiology of acute infection. 
In many of the studies of hospitalized pneumonia 
patients in whch evidence of TWAR infection has 
been found, there has been a portion of the patients 
with evidence of infection with pneumococcus and 
influenza A [29-331. The etiologic role of W A R  in 
these apparent dual infections is not known. More than 
one potential etiologic agent for cases of pneumonia 
has been described in the past. Influenza A has been 
thought to play an initiating role in bacterial 
pneumonia. Studies of multiple etiologies of cases of 
infectious dsease have.not provided clear-cut answers. 
Many bacterial pathogens may be present in the upper 
respiratory tract without associated disease. C. pneu- 
moniue may be similar, and determining what organisms 
are primarily responsible when disease occurs will be 
diff1CUlt. 
DIAGNOSTIC METHODS 
Another need for hture research is for simpler, more 
rapid methods of diagnosis. While there is hope that 
the PCR method will offer more rapid identification 
of the organism in clinical specimens, this is not a 
simple or an inexpensive test, and as with other PCR 
tests, problems with inhibitors exist. 
The MIF test has been the standard serologic test 
for Chlamydia for 25 years. It is the only sensitive and 
specific test now available. Unfortunately, it is 
technically demanding, relatively expensive and unsuit- 
able for the clinical laboratory. It is not a test that can 
be left in the hands of technicians without close 
oversight. With the expanded interest in C. pneumoniae, 
many laboratories have undertaken MIF studies with 
t h i s  organism and some have been reporting question- 
able results. Problems with lack of specificity and some 
high titer results are due to lack of care in determining 
specific staining. The only positive reaction in the test 
is immunofluorescence, uniformly distributed and 
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Table 3 Seroepidemiologic studies: C pneumoniae antibody and coronary artery disease 
Location Case/control Antibody OR 95% CI 
Finland 70141 IgG 32+ 3 .P  1.4-10.7 
Finland low102 IgA 64+ 2.3 0.9-6.2 
Seattle 461195 IgG 16+ 1.6 1.0-2.7 
Seattle 171/120 ' IgG 8+ 2.6 1.4-4.8 
Finland 46/46 Imm. comp 3.9" 1.3-12.0 
Sweden 60160 IgG 32+ 3.9 1.1-15.2 
USA - ARICb 3261326 IgG 8+ 2 1.2-3.4 
Not adjusted for risk factors 
Carotid artery disease. 
associated with the outer edge of the elementary 
bodies. A simpler test with automatic interpretation 
would be very helpful for diagnosis of TWAR 
infection. 
The labilitity of the specific antigens of C. pneu- 
moniae has so far prevented their detailed identi- 
fication. Since neutralizing antibodies can be produced, 
it may be possible to idendy, isolate and produce the 
specific antigen both for laboratory tests and for a 
possible vaccine. 
FUTURE OF C. PNEUMONIA€ IN CHRONIC DISEASE 
While a number of questions remain concerning the 
role of C. pneumoniae in acute respiratory tract 
infections, the most exciting and potentially most 
important area for future research is in the role of C. 
pneumoniae in chronic diseases. It is now clear that 
following acute infections it is common for the 
organism to persist in the body. The challenge is to 
determine the aetiologic significance of these persistent 
organisms in chronic disease. 
Among the chronic diseases for which some 
association with C. pneumoniae has been reported are: 
asthma [26,34,35], atherosclerosis, chronic obstructive ' 
Table 4 TWAR and atherosclerosis: summary of six studies 
pulmonary disease [36,37], reactive arthritis [38,39], 
and sarcoidosis [40,41]. Among these conditions, by far 
the most important to human health is atherosclerosis. 
The most extensive data associating C. pneumoniae with 
chronic disease exist for atherosclerosis. The association 
has been demonstrated both by seroepidemiology and 
by morphologic and microbiological methods. 
Saikku and his colleagues were the first to show 
that persons with coronary artery disease more 
fiequently had TWAR antibody than controls [42]. He 
extended this observation to different population 
groups and demonstrated the association with different 
classes of TWAR antibody [43-45]. These observations 
have been supported by seroepidemiologic studies by 
other investigators [46-48] and have been extended to 
include carotid artery thickening as determined by B- 
mode ultrasonograph [49] (Table 3). 
In a series of studies we have shown that the C. 
pneumoniae organism can be found in over 50% of 
developed atheromatous lesions [50-561 (Table 4). The 
presence of organisms in tissue has been demonstrated 
by immunocytochemistry (ICC) udizing both genus 
and species-specific monoclonal antibodies, the PCR 
test for C. pneumoniae, and electron microscopy. Table 
5 shows the series of six studies of a total of 285 persons 
Atheroma 
Study Normals Initial Developed 
Coronary - S. Mica^ 
Aorta - Umversity of Washingtonb 
Coronary - PDAYa 
Coronary, atherectomy - University of 
Coronary - Alaska" 
Carohd, endarterectomy - California, 
Washington 
Washmgton 
0/8 7/16 
014 1 /4 
0131 2/11 
None Primary lesion 
013 6/19 
0/6 Fresh-frozen 
Restenosis 
Formalin fured 
44% 13/20 
25% 6/17 
18% 6/7 
10/23 
10/15 
32% 17/40 
515 
32/56 
65% 
35% 
86% 
43% 
67% 
43% 
100% 
57% 
Posiuve by ICC or PCR/no. tested. 
PDAY = USA mulucenter study 'Pathobiological deternunants of atherosclerosis in youth'. 
^Autopsy stumes 
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Table 5 Routine autopsies of 39 patients ?WAR in tissues 
TWAR-positive tissue" Number 
Cardiovascular only 11 
one spleen) 3 
Non-cardiovascular only (two lung, 
Cardiovascular and non-cardiovascular tissue 7 
TWAR-nemtive tissue 18 
'By ICC or PCR. 
in which the organism has been demonstrated in 
atheromatous lesions of coronary and carotid arteries 
and aorta. 
The tissue studIed came fiom autopsy, surgery and 
atherectomy. The populations studied came fiom 
throughout the continental USA, South Africa and 
Alaska. Persons studied included Caucasians, Blacks 
and Alaska Natives. C. pneumoniae was present in 
atheroma of all these populations and in both genders. 
The organism was found in beginning lesions in young 
persons and in well-developed and calcified lesions of 
older persons. The organism was never found in 
normal arterial specimens. However, true matched 
controls without atherosclerosis were available only in 
a study of young persons (15 to 34 years of age) in the 
US Multicenter PDAY study, where 31 normals fded  
to show C. pneumoniae [54]. 
ICC has proven to be more sensitive than PCR in 
demonstrating TWAR organisms in tissue. This can 
be accounted for in part by the known fact that 
formalin fixation and parafEin block mounting decrease 
PCR sensitivity. We have also demonstrated that the 
full sensitivity of the ICC method is not obtained if 
only one section is stained and examined for each 
atherosclerotic lesion. When a series of sections are 
made of merent depths through a lesion, sometimes 
both positive and negative slides are obtained. We 
therefore estimate that while a high fiequency of 
TWAR-positive lesions is demonstrated in our studies 
shown in Table 4, the results are nevertheless an 
underestimation, since false negatives undoubtedly 
exist among the single 4 pm sections examined for each 
of the lesions. 
The demonstration of C. pneumoniae in athero- 
sclerotic lesions has recently been hrther confirmed by 
the results of a multicenter study organized by 
Summersgill, u t ihng  coronary arteries fiom 12 hearts 
excised fiom patients prior to heart transplantation. 
While C. pneumoniae was demonstrated in tissue fiom 
over half of these patients by ICC and/or PCR, the first 
isolation of the TWAR organism from coronary artery 
was accomplished fiom one of the patients in three 
separate laboratories [57]. 
While there is now solid evidence that C. pneu- 
moniae is frequently present in atherosclerotic lesions, 
there is only circumstantial evidence that the presence 
of the organism is related to the pathogenesis of the 
disease. A possible null hypothesis is that the TWAR 
organisms may persist in cells indefimtely in a way 
similar to that of certain viruses that may persist for life 
after infection and not cause pathology. 
In order to explore the fiequency with which 
TWAR organisms persist in various tissues, we tested 
multiple tissues obtained at autopsy h m  39 patients at 
the University of Washington Medical Center [58]. 
Half had cardiovascular disease recognized before 
death, and all of them had tissue available fiom 
coronary arteries, lung, liver and spleen. The results of 
testing these formahfixed and par&-mounted 
blocks by ICC and PCR can be seen in Table 5. 
Twenty-one of the patients had TWAR demonstrated 
in one or more tissues. Eighteen had the organism in a 
cardiovascular tissue, and three only in a non- 
cardiovascular tissue. Those three consisted of two 
patients with the organism only in lung tissue, and one 
only in the spleen. Of the 18 with the organism in 
cardiovascular tissue, 11 had it only in that dssue, and 
seven in both cardiovascular and non-cardiovascular 
tissues. The card~ovascular tissue examined included 
coronary arteries (13 positive/37 tested), myocardium 
(5/17) and venous coronary bypass vessels (112). The 
number of positives for other tissue were lung (5/39), 
liver (4/39), spleen (2/39), bone marrow (2/20) and 
lymph nodes (1/12). 
While the study shows that TWAR may be 
detected in non-cardiovascular tissue, it also shows 
that the organism is much more fiequently found in 
cardiovascular tissue. We interpret these results as 
circumstantial evidence for the possibility that the 
"WAR organism is playing a causative role in athero- 
sclerosis. 
Another possible explanation for the fiequent 
presence of TWAR in atheroma is that the originally 
infected lung macrophages are attracted to granuloma- 
like lesions throughout the body, including atheroma. 
We therefore looked with ICC and PCR at a series of 
39 surgical or autopsy specimens of granuloma. Table 
6 shows that the TWAR organism was found in only 
three specimens, all of which were sarcoid granulomas 
of the skm. We are uncertain of the meaning of the 
finding with sarcoidosis. An association with TWAR 
and sarcoidosis was demonstrated serologically many 
years ago [40]. At this time we can only recommend 
more studies of sarcoid tissue. 
We believe that the association of C. pneumoniae 
and atherosclerosis has been amply demonstrated by 
observational studies, and that the fkequency of TWAR 
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Table 6 TWAR in granulomas 
No. positive ICC 
Disease No. tissue specimens or PCR 
Tuberculosis 8 0 
Sarcoidosis 16 3 
Xanthelasma 3 0 
Rheumatoid 2 0 
Crohn's disease 2 0 
Giant cell tumor 2 0 
Xanthoma choroid plexus 1 0 
Other 5 0 
in atheroma cannot be explained by the null hypo- 
thesis that TWAR exists in macrophages throughout 
the body or in granuloma. Future studies should 
emphasize more direct exploration of the etiologic role 
that C. pneumoniae might play in atherosclerosis. Such 
studies can uthze animal models of atherosclerosis and 
clinical trials in humans. Several established animal 
models of atherosclerosis are avadable. More recently, 
genetic knock-out models in mice have become 
available that may offer additional opportunity. In 
preliminary experiments we have failed to establish a 
meaningfill TWAR infection in the Watanabe heritable 
hyperlipidemic rabbit model of atherosclerosis. We have 
been successful in producing a TWAR infection in the 
ApoE-deficient mouse model of atherosclerosis [59]. 
While clinical trials in humans will be difficult, 
they will be necessary for final proof of an etiologic 
relationship. Such trials could be of antibiotic treatment 
directed at preventing or modifymg atherosclerotic 
disease or its complications. The approach would be 
similar to that used to prove an etiologic association of 
Helicobacter pylori with peptic ulcer disease. 
FUTURE OF MACROLIDES 
Antibiotic treatment of chlamydial infections has had 
both successes and failures. Mass antibiotic campaigns 
against endemic trachoma were disappointing. While 
some modifications of the severity of the illness were 
sometimes observed, eradication of infection was not 
obtained. Late relapse of acute C. trachomatis con- 
junctival infection has been observed in patients with 
apparent healed and scarred disease. Viable organism 
has been demonstrated in deep scarified tissue by in situ 
hybridization. Antibiotic treatment of acute superficial 
genital tract infections has been successful in alleviating 
symptoms and reducing transmission. However, it is 
probable that the cure as demonstrated by clinical 
symptoms or by culture negativity has been greatly 
overstated, and that persistence of the organism in the 
genital tract tissue is common. Fallopian tube scarring 
with resulting infertility has been observed both in 
women without a history of acute infection and in 
those treated for acute infection. C .  trachomatis has been 
demonstrated in these scarred tubes by in situ 
hybridization [60]. 
In some cases W A R  pulmonary infection symp- 
toms may spontaneously disappear and others may 
respond readily to a single course of antibiotic. How- 
ever, in some cases additional antibiotic therapy has 
been necessary for complete relief of symptoms. A 
number of instances of isolation of the organism &om 
throat swab samples following antibiotic treatment have 
been observed. 
As has been true since the beginning of antibiotic 
therapy for trachoma, there is a need for an antibiotic 
that will truly eradicate the Chlamydia organisms from 
the body and not merely suppress Chlamydia growth 
and promote the disappearance of acute symptoms. As 
important as a cure of acute disease and prevention of 
transmission is, the prevention of chronic, latent or 
persistent infection also deserves attention. At this time 
the newer macrolide drugs with greater cellular pene- 
tration and fewer gastrointestinal side effects appear to 
be the drugs of choice for acute Chlamydia infection. 
Whether they will be more effective in preventing 
persistent infection or whether, because of their 
minimal side effects, they can be used in longer treat- 
ment regimens to treat persistent infection, is an 
important problem for investigation. 
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